MGMaria Carmen Garganese

Maria Carmen Garganese

*This is an algorithmically generated author record based on publicly available information.

Maria Carmen Garganese has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Unusual Presentation of Relapse in Neuroblastoma

    by Maria Felicia Villani, Maria Luisa D’Andrea, Aurora Castellano, Milena Pizzoferro, Maria Carmen Garganese

    Neuroblastoma is the most common extracranial solid tumor in children and accounts for 8% to 10% of all childhood cancers. The spread of metastases is both lymphatic and hematogenous. Hematogenous route occurs most commonly in bone marrow and cortical bone; pancreatic metastases are very rare, and there are few reports about this topic in medical literature. We report the case of a 14-year-old boy who suffers a third relapse of neuroblastoma: in this patient 123I-MIBG confirms that lesions detected by CT were due to a relapse in pancreatic tissue and influenced subsequent therapeutic management.


  • Open Access

    Local control in metastatic neuroblastoma in children over 1 year of age

    by Maria Antonietta De Ioris, Alessandro Crocoli, Benedetta Contoli, Maria Carmen Garganese, Gianluigi Natali, Paolo Tomà, Alessandro Jenkner, Renata Boldrini, Maria Debora De Pasquale, Giuseppe Maria Milano, et al.

    Local control is always considered in metastatic neuroblastoma (NBL). The aim of this study is to evaluate the impact of radical surgery on survival in children over 1 year of age. Fifty-eight patients older than 1 year of age with metastatic NBL were treated with conventional plus high-dose chemotherapy with or without addition of local radiotherapy (RT, 21Gy). Surgery was classified as radical surgery (complete resection and gross total resection) or non-radical surgery. The Kaplan-Meier method and the Cox proportional hazard model were used to calculate the probability of progression free and overall survival (PFS and OS) and for multivariate analysis. The 5-year PFS and OS for patients with radical surgery were 26% (95% CI 14-40%) and 38% (95% CI 23-53%) respectively, while the PFS and OS for patients without radical surgery were 33% (95% CI 10-59%) and 31% (95% CI 10-55%) (respectively, P 0.85 and P 0.42). The 5-year PFS and OS for patients who received RT were 36% (95% CI 19-53%) and 46% (95% CI 26-64%) respectively, while the 5-year PFS and OS for patients who did not receive RT were 22% (95% CI 9-38%) and 27% (95% CI 13-42%) respectively (P 0.02 for PFS). Multivariate analysis confirmed the role of well-known prognostic factors, such as the presence of MYCN amplification, age and response before high-dose chemotherapy. Our data suggest that the degree of resection does not influence survival in metastatic NBL patients treated with high-dose chemotherapy; local RT contributes to local disease control.


    • 1 December 2012
      • Vol. 32  (12) , 5527-33

    Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma.

    by Maria Antonietta De Ioris, Benedetta Contoli, Alessandro Jenkner, Maria Debora De Pasquale, Annalisa Serra, Luigi De Sio, Rosanna Pessolano, Maria Carmen Garganese, Alessandro Crocoli, Teresa Corneli, et al.

    Although high-dose chemotherapy (HDC) represents the standard of treatment for high-risk neuroblastoma (NBL), the most effective conditioning regimen still remains to be identified. Forty-one high-risk NBL entered into local protocol based on induction chemotherapy, surgery and HDC with either etoposide/thiotepa/cyclophophamide (ETC) or i.v. busulfan and L-PAM (Bu/L-PAM). Thirty-seven patients underwent HDC; 29 with ETC and 8 with Bu/L-PAM. No toxic deaths were recorded. The 5-year progression-free survival (PFS) of patients given ETC was 21% (95% confidence interval CI (9-36%), while PFS for patients given Bu/L-PAM was 88% (95% CI=39-98%) (p<0.05). In multivariate analysis, treatment with the ETC regimen predicted progression/recurrence with a hazard ratio (HR) of 16.8 (p<0.05), as well as MYCN amplification which had an HR of 4.4 (p<0.05). Although the number of studied cases is limited, our data suggest that in high-risk NBL the combination of Bu/L-PAM is superior to the ETC regimen.


  • Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma

    by Maria Antonietta De Ioris, Aurora Castellano, Ilaria Ilari, Maria Carmen Garganese, Gianluigi Natali, Alessandro Inserra, Rita De Vito, Lucilla Ravà, Maria Debora De Pasquale, Franco Locatelli, et al.